Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueGross MarginNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Sales

Pharming (PHAR) EBIT Margin (2020 - 2025)

Historic EBIT Margin for Pharming (PHAR) over the last 6 years, with Q3 2025 value amounting to 125.69%.

  • Pharming's EBIT Margin rose 1202000.0% to 125.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.04%, marking a year-over-year increase of 138900.0%. This contributed to the annual value of 2.9% for FY2024, which is 7000.0% down from last year.
  • As of Q3 2025, Pharming's EBIT Margin stood at 125.69%, which was up 1202000.0% from 2.21% recorded in Q2 2025.
  • Over the past 5 years, Pharming's EBIT Margin peaked at 484.88% during Q1 2022, and registered a low of 29.35% during Q1 2024.
  • For the 5-year period, Pharming's EBIT Margin averaged around 32.59%, with its median value being 0.52% (2021).
  • As far as peak fluctuations go, Pharming's EBIT Margin crashed by -522000bps in 2021, and later skyrocketed by 4704600bps in 2022.
  • Quarter analysis of 5 years shows Pharming's EBIT Margin stood at 15.69% in 2021, then fell by -19bps to 18.68% in 2022, then soared by 64bps to 6.63% in 2023, then crashed by -40bps to 9.3% in 2024, then skyrocketed by 1451bps to 125.69% in 2025.
  • Its last three reported values are 125.69% in Q3 2025, 2.21% for Q2 2025, and 8.91% during Q1 2025.